Resistance of pleural mesothelioma cell lines to apoptosis: Relation to expression of Bcl-2 and Bax

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 275, Issue 1 19-1, 1998, Pages

  Narasimhan, Sudha Rani ^a   Yang, Lin ^a   Gerwin, Brenda I ^b   Broaddus, V Courtney ^a,c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asbestos; Cancer; Mesothelial cell; p53; Reactive oxygen species

Indexed keywords

ASBESTOS;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; HUMAN; HUMAN CELL; MESOTHELIOMA; MESOTHELIUM; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0031817980     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.1998.275.1.l165     Document Type: Article

References (46)

1. Aguilar-Santelises, M., M. E. Rottenberg, N. Lewin, H. Mellstedt, and M. Jondal. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int. J. Cancer 69: 114-119, 1996.
2. BéruBé, K. A., T. R. Quinlan, H. Fung, J. Magae, P. Vacek, D. J. Taatjes, and B. T. Mossman. Apoptosis is observed in mesothelial cells after exposure to crocidolite asbestos. Am. J. Respir. Cell Mol. Biol. 15: 141-147, 1996.
3. Boise, L. H., M. Gonzalez-Garcia, C. E. Postema, L. Ding, T. Lindsten, L. A. Turka, X. Mao, G. Nunez, and C. B. Thompson. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
4. Bowman, R. V., L. S. Manning, M. R. Davis, and B. W. S. Robinson. Chemosensitivity and cytokine sensitivity of malignant mesothelioma. Cancer Chemother. Pharmacol. 28: 420-426, 1991.
5. Boylan, A. M., D. A. Sanan, D. Sheppard, and V. C. Broaddus. Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin αvβ5. J. Clin. Invest. 96: 1987-2001, 1995.
6. Brambilla, E., A. Negoescu, S. Gazzeri, S. Lantuejoul, D. Moro, C. Brambilla, and J.-L. Coll. Apoptosis-related factors p53, Bcl-2, and Bax in neuroendocrine lung tumors. Am. J. Pathol. 149: 1941-1952, 1996.
7. Broaddus, V. C. Asbestos, the mesothelial cell and malignancy: a matter of life or death. Am. J. Respir. Cell Mol. Biol. 17: 657-659, 1997.
8. Broaddus, V. C., L. Yang, L. M. Scavo, J. D. Ernst, and A. M. Boylan. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J. Clin. Invest. 98: 2050-2059, 1996.
9. Chilosi, M., F. Gacchetti, A. P. Dei Tos, M. Lestani, M. Morassi, G. Martignoni, C. Sorio, A. Benedetti, L. Morelli, and C. Doglioni. Bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J. Pathol. 181: 362-367, 1997.
10. Chittenden, T., E. A. Harrington, R. O'Connor, C. Flemington, R. J. Lutz, G. I. Evan, and B. C. Guild. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374: 733-736, 1995.
11. Chresta, C. M., J. R. W. Masters, and J. A. Hickman. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res. 56: 1834-1841, 1996.
12. Egle, A., A. Villunger, I. Marschitz, M. Kos, A. Hittmair, P. Lukas, K. Grünewald, and R. Greil. Expression of Apo-1/Fas, Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Br. J. Haematol. 97: 418-428, 1997.
13. 2+ and phospholipid binding domains. Biochem. Biophys. Res. Commun. 200: 867-876, 1994.
14. Flomerfelt, F. A., and R. L. Miesfeld. Recessive mutations in a common pathway block thymocyte apoptosis induced by multiple signals. J. Cell Biol. 127: 1729-1742, 1994.
15. Gabrielson, E. W., A. Van der Meeren, R. R. Reddel, H. Reddel, B. I. Gerwin, and C. C. Harris. Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos. Carcinogenesis 13: 1359-1363, 1992.
16. Gagnon, J., J. M. Roth, M. Carroll, R. Hofmann, K. A. Haycock, J. Plamondon, D. S. Feldman, and J. Simpson. SuperANOVA: Accessible General Linear Modeling. Berkeley, CA: Abacus Concepts, 1989, p. 1-316.
17. Gazzaniga, P., A. Gradilone, R. Vercillo, O. Gandini, I. Silvestri, M. Napolitano, L. Albonici, A. Vincenzoni, M. Gallucci, and L. Frati. Bcl-2/Bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int. J. Cancer 69: 100-104, 1996.
18. Han, J., P. Sabbatini, D. Perez, L. Rao, D. Modha, and E. White. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev. 10: 461-477, 1996.
19. Herod, J. J. O., A. G. Eliopoulos, J. Warwick, G. Niedobitek, L. S. Young, and D. J. Kerr. The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 56: 2178-2184, 1996.
20. Hung, W. C., and L. Y. Chuang. Induction of apoptosis by sphingosine-1-phosphate in human hepatoma cells is associated with enhanced expression of bax gene product. Biochem. Biophys. Res. Commun. 229: 11-15, 1996.
21. Jiang, S. X., T. Kameya, Y. Sato, N. Yanase, H. Yoshura, and T. Kodama. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am. J. Pathol. 148: 837-846, 1996.
22. Kuypers, F. A., R. A. Lewis, M. Hua, M. A. Schott, D. Discher, J. D. Ernst, and B. H. Lubin. Detection of altered membrane phospholipid asymmetry in subpopulations of human red cells using fluorescently labeled annexin V. Blood 87: 1179-1187, 1996.
23. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
24. Lu, Q.-L., A. M. Hanby, M.A. N. Hajibagheri, S. E. Gschmeissner, P.-J. Lu, J. Taylor-Papadimitriou, S. Krajewski, J. C. Reed, and N. A. Wright. Bcl-2 protein localizes to the chromosomes of mitotic nuclei and is correlated with the cell cycle in cultured epithelial cell lines. J. Cell Sci. 107: 363-371, 1994.
25. McDonnell, T. J., P. Troncoso, S. M. Brisbay, C. Logothetis, L. W. K. Chung, J.-T. Hsieh, S.-M. Tu, and M. L. Campbell. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52: 6940-6944, 1992.
26. Meijerink, J. P. P., R. F. C. M. Smetsers, A. W. Slöetjes, E. H. R Linders, and E. J. B. M. Mensink. Bax mutations in cell lines derived from hematological malignancies. Leukemia 9: 1828-1832, 1995.
27. Metcalf, R. A., J. A. Welsh, W. P. Bennett, M. B. Seddon, T. A. Lehman, K. Pelin, K. Linnainmaa, L. Tammilehto, K. Mattson, and B. I. Gerwin. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 52: 2610-2615, 1992.
28. Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, D. A. Liebermann, B. Hoffman, and J. C. Reed. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
29. Mor, O., P. Yaron, M. Huszar, A. Yellin, O. Jakobovitz, F. Brok-Simoni, G. Rechavi, and N. Reichert. Absence of p53 mutations in malignant mesotheliomas. Am. J. Respir. Cell Mol. Biol. 16: 9-13, 1997.
30. Mossman, B. T., D. W. Kamp, and S. A. Weitzman. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 14: 466-480, 1996.
31. Naumovski, L., and M. L. Cleary. Bcl-2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. Blood 83: 2261-2267, 1994.
32. Oltvai, Z. N., and S. J. Korsmeyer. Checkpoints of dueling dimers foil death wishes. Cell 79: 189-192, 1994.
33. Oltvai, Z. N., C. L. Milliman, and S. J. Korsmeyer. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
34. Ong, S. T., and N. J. Vogelzang. Chemotherapy in malignant pleural mesothelioma. A review. J. Clin. Oncol. 14: 1007-1017, 1996.
35. Rampino, N., H. Yamamoto, Y. Ionov, Y. Li, H. Sawai, J. C. Reed, and M. Perucho. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969, 1997.
36. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124: 1-6, 1994.
37. Reynolds, J. E., T. Yang, L. Qian, J. D. Jenkinson, P. Zhou, A. Eastman, and R. W. Craig. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res. 54: 6348-6352, 1994.
38. Sedlak, T. W., Z. N. Oltvai, E. Yang, K. Wang, L. H. Boise, C. B. Thompson, and S. J. Korsmeyer. Multiple bcl-2 family members demonstrate selective dimerizations with bax. Proc. Natl. Acad. Sci. USA 92: 7834-7838, 1995.
39. Segers, K., M. Ramael, S. K. Singh, J. Weyler, J. Van Meerbeeck, P. Vermeire, and E. Van Marck. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch. 424: 631-634, 1994.
40. Silvestrini, R., E. Benini, S. Veneroni, M. G. Daidone, G. Tomasic, P. Squicciarini, and B. Salvadori. p53 and bcl-2 expression correlates with clinical outcome in a series of nodepositive breast cancer patients. J. Clin. Oncol. 14: 1604-1610, 1996.
41. Steller, H. Mechanisms and genes of cellular suicide. Science 267: 1445-1449, 1995.
42. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
43. Williams, G. T. Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097-1098, 1991.
44. Willingham, M. C., and K. Bhalla. Transient mitotic phase localization of Bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis. J. Histochem. Cytochem. 42: 441-450, 1994.
45. Yang, E., J. Zha, J. Jockel, L. H. Boise, C. B. Thompson, and S. J. Korsmeyer. Bad, a heterodimeric partner for Bcl-xl and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
46. Yin, X.-M., Z. N. Oltvai, and S. J. Korsmeyer. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369: 321-323, 1994.